Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV

Inclusion Criteria: * Signed informed consent * Male or female, aged 18-45 years, in good health. * Negative for HCMV * Body mass index between 19 and 32 kg/m² * Willing to forego receipt of other routine vaccinations (with the exception of seasonal influenza vaccination) for five months after study entry. * For female volunteers: use of effective birth control for at least 2 months prior to study entry and willing to use effective birth control measures up to the Month 12 visit * Comply with the requirements of this protocol (e.g. return for follow-up visits), as judged by the Investigator. Exclusion Criteria: * Works as a childcare provider. * Pregnant or breastfeeding woman. * Any screening safety laboratory value that is 2 times above the upper limit of normal value. * Any confirmed or suspected immunodeficiency or autoimmune disorder. * Treatment with any chronic immunosuppressive medication or other immuno-modifying drugs within 6 months prior to study entry. However, inhaled and topical steroids are allowed. * Any vaccination other than for seasonal influenza within 3 months prior to study entry. * Previous vaccination with an investigational HCMV vaccine. * Receipt of blood, blood products and/or immunoglobulins within 3 months prior to study entry. * History of severe allergic reactions and /or anaphylaxis * Allergy to any component of the vaccine preparation. * Expected to be unavailable to complete study follow up. * Tested positive for HIV, HBsAg and/or anti-HCV. * Participating in another clinical trial. * Subject with a rash, dermatological condition or tattoos in the area of the injection site, as these may interfere with administration site reaction rating.